New 'Living Drug' trial targets Tough-to-Treat cancers
NCT ID NCT05672459
Summary
This study is testing a new type of personalized cell therapy called IVS-3001 in adults with advanced solid tumors that have stopped responding to standard treatments. The therapy involves modifying a patient's own immune cells to recognize and attack cancer cells that carry a specific marker called HLA-G. The main goals are to find a safe dose and see if the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.